About Point Application with Chuankezhi intramuscular children with recurrent respiratory tract infection 35 cases.docVIP

 PAGE \* MERGEFORMAT 12 About Point Application with Chuankezhi intramuscular children with recurrent respiratory tract infection 35 cases [Abstract] Objective To observe the Winter Disease Chuankezhi Point Application with intramuscular treatment efficacy in children with recurrent respiratory tract infections, improvement of symptoms in children and salivary secretory immunoglobulin A (sIgA) levels. Methods recurrent respiratory tract infection were randomly divided into two groups with the control group of 35 patients with simple point application Winter Disease treatment group 35 patients given Winter Disease Chuankezhi Point Application with intramuscular injection and was observed before and after treatment the improvement of clinical symptoms in children and the determination of the level of sIgA in saliva of children. The results improve the clinical efficacy of the treatment group, improvement of symptoms and sIgA is better than the control group, the difference was statistically significant (P lt;0.05. Conclusion Winter Disease Chuankezhi Point Application with intramuscular injection to improve the children with recurrent respiratory tract infections clinical efficacy in children, symptoms, significantly improve the effect of salivary sIgA, children with recurrent respiratory tract infection prevention and treatment of an effective method. [Keywords:] point application; Chuankezhi injection, repeated respiratory infection Recurrent respiratory tract infections (recurrent respiratory tract infection, RRTI) in children common disease, accounting for about 10 children aged ≤ 6%, especially common in children ≤ 3 years of age [1]. The disease has recurrent, lingering illness is difficult The more the characteristics of life in children with a greater impact health and learning. Our clinical Winter Disease Treatment Point Application method RRTI, a significant effect, are reported below. 1 Clinical data 1.1 Case Source 2005 to 2006 in o